10 February 2025 – Sydney, Australia | BlinkLab Limited (ASX:BB1) ("BlinkLab" or "the Company"), an innovative digital healthcare company utilising AI-powered smartphone technology as part of a neurodevelopmental diagnostic approach, is pleased to announce that North Shore Pediatric Therapy (NSPT) has joined its US registrational study as the second clinical site.
NSPT, a well-known provider of early autism intervention in the Chicago area of the United States, will play an important role in the 100-patient initial phase of the BlinkLab Dx 1 study, with patient recruitment and diagnostic testing set to begin in weeks to come.
Highlights
-
NSPT has joined PriMED Clinical Research as the second US-based clinical site in BlinkLab’s autism diagnostic registrational study.
-
NSPT specialises in early autism intervention, offering Applied Behavior Analysis (ABA), neuropsychology, speech therapy, and occupational therapy.
-
NSPT’s team is highly experienced in administering ADOS-2, the gold standard for autism diagnosis.
-
NSPT’s recruitment reach includes a diverse population, ensuring robust and high-quality data collection.
-
With two leading US-based autism centers onboard, BlinkLab expects faster enrollment and strong data collection to support its FDA pathway.
The study will serve as a benchmark for standard-of-care comparisons, validating the accuracy of BlinkLab’s AI-powered smartphone diagnostic tool against traditional autism assessments like ADOS-2.
NSPT’s ability to diagnose children as young as 18 months old aligns with BlinkLab’s mission to enable early autism detection and improve long-term outcomes through earlier intervention.
About North Shore Pediatric Therapy
NSPT is a leading provider of pediatric therapy and diagnostic services in Chicago, specializing in autism evaluation and intervention. NSPT’s multidisciplinary approach includes ABA therapy, speech and occupational therapy, mental health services, and neuropsychological diagnostics, ensuring comprehensive care for children with developmental challenges.
For Further Information:
Dr. Henk-Jan Boele
Chief Executive Officer
BlinkLab Limited
[email protected]
Brian Leedman
Non-Executive Chairman
BlinkLab Limited
[email protected]
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
About us:
About BlinkLab Limited
BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.
For more information, visit www.blinklab.org
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
